Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: June 2014


Suggested reading

Ahmad S, Ellis JC, Amend H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomized trial. Lancet 2006; 367: 1555–1556.
Appleton R, Macleod S, Maryland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database of Systematic Reviews 2008; 3: CD001905.
Armstrong DL, Battin MR. Pervasive seizures caused by hypoxic-ischemic encephalopathy: treatment with intravenous paraldehyde. Journal of Child Neurology 2001; 16: 915–917.
Bostrom B. Paraldehyde toxicity during treatment of status epilepticus. American Journal of Diseases in Children 1982; 136: 414–415.
Chin RF, Neville BG, Packham C, Wade A, Bedford H, Scott RC. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurology 2008; 7: 696–703.
Curless RG, Holzman BH, Ramsay RE. Paraldehyde therapy in childhood status epilepticus. Archives of Neurology 1983; 40: 477–480.
Johnson CE, Vigoreaux JA. Compatibility of paraldehyde with plastic syringes and needle hubs. American Journal of Hospital Pharmacy 1984; 41: 306–308.
Ramsay RE. Pharmacokinetics and parenteral use of phenytoin, phenobarbital, and paraldehyde. Epilepsia 1989; 30(Suppl 2): S1–S3.
Welty TE, Cloyd JC, Abdel-Monem MM. Delivery of paraldehyde in 5% dextrose and 0.9% sodium chloride injections through polyvinyl chloride IV sets and burettes. American Journal of Hospital Pharmacy 1988; 45: 131–135.